Indivior Pharmaceuticals has delivered four consecutive earnings beats with an average positive surprise exceeding 60%, trades at a forward price-to-earnings ratio of 9.8x with a PEG of 0.12, and carries best-in-class peer-relative margins — a combination of execution and valuation that makes the risk/reward favorable at current levels, tempered by a cash-conversion gap and 13% short interest that warrant ongoing monitoring.
Thesis pillars
- Best In Class Peer Margins→Stable
- Perfect Four Quarter Beat Streak→Stable
- Attractive Valuation Low Peg↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Momentum Cont setup
Conditional: death cross active — below strong-conviction threshold. Size accordingly.
Healthcare · Drug Manufacturers - Specialty & Generic
Buy now at $28.15. A.R:R 4.5:1 at $28.15 — the engine's gate value (upside to target $42.07 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$14 per share to target.
Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine injection, $856 million global net sales in 2025) and SUBOXONE Film ($346 million) — with 85% of net revenues generated in the U.S. SUBLOCADE accounted for 69% of... Read more
Buy now at $28.15. A.R:R 4.5:1 at $28.15 — the engine's gate value (upside to target $42.07 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$14 per share to target. Chart setup: Trend continuation, RSI 55, MACD bullish. Deep value: 59% margin of safety. Extreme undervaluation. Score 7.0/10, high confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 111d clear, semi cycle peak clear, materials cycle peak clear, sector concentration cap sector=healthcare 5/10 self excluded). Suitability: aggressive.
About Indivior Pharmaceuticals, Inc.
About Indivior Pharmaceuticals, Inc.
SUBLOCADE, Indivior Pharmaceuticals' monthly injectable buprenorphine for opioid use disorder, generated $856 million in global net sales in 2025 — 69% of total net revenues, up from 64% in 2024. SUBOXONE Film contributed $346 million in global net sales. The U.S. accounted for 85% of net revenues in both 2025 and 2024. The FDA granted SUBLOCADE a label expansion on February 24, 2025, adding rapid initiation and alternative injection sites.
Indivior generates revenue through prescription sales of SUBLOCADE and SUBOXONE Film, with SUBLOCADE distributed through a closed specialty pharmacy network using a REMS protocol that prevents patients from taking direct possession of the drug. Over 88% of U.S. insured lives have SUBLOCADE coverage and more than 95% of patients enrolled in the co-pay program paid zero out of pocket in 2025. Revenues from SUBOXONE Film are declining: under a 2020 Department of Justice Resolution Agreement, the company may not employ a sales force to promote SUBOXONE Film in the U.S., and a separate opioid MDL settlement restricts marketing through 2032. The company completed its obligations under the Resolution Agreement, including $600 million in total payments, in November 2025. Outside the U.S., Indivior sells products in Canada, Australia, France, and Germany, having exited the U.K., Ireland, Sweden, Israel, Finland, and Italy in October 2025.
Show full overview
Indivior's manufacturing relies almost exclusively on third-party contract manufacturers for sterile fill and finished-dose production. The 10-K discloses that the company relies on either a single or dual source of supply for raw materials, product components, and APIs for most marketed products, including buprenorphine. Technology transfer to a new supplier averages 36 months per the filing and requires separate FDA approval of any new manufacturing site, meaning a supply disruption at a primary CMO could affect commercial availability for multiple years. Any delay could also violate contractual delivery obligations.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Indivior Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Indivior Pharmaceuticals, Inc.
Latest news
- NEWS Indivior Pharmaceuticals (INDV) CFO Dec acquired 14,059 shares - Quantisnow — Quantisnow Nov 4, 2026 positive
- NEWS A Look at Indivior Pharmaceuticals Inc (INDV) After 22.4% Decline -- GF Value $25.53 vs Price $28.15 - GuruFocus — GuruFocus Nov 4, 2026 negative
- NEWS (INDV) Indivior Expects 2026 Net Revenue Range $1.30B to $1.37B, vs. FactSet Est of $1.33B - marketscreener.com — marketscreener.com Oct 29, 2026 neutral
- NEWS (INDV) Indivior Expects 2026 Net Revenue Range $1.30B to $1.37B, vs. FactSet Est of $1.33B - www.marketscreener.com — www.marketscreener.com Oct 29, 2026 neutral
- NEWS Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $1.32 per Share, vs. FactSet Est of $1.06 - w — www.marketscreener.com Oct 29, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:29:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Buy now at $28.15. A.R:R 4.5:1 at $28.15 — the engine's gate value (upside to target $42.07 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$14 per share to target. Chart setup: Trend continuation, RSI 55, MACD bullish. Deep value: 59% margin of safety. Extreme undervaluation. Target $42.07 (+49.4%), stop $26.18 (−7.5%), A.R:R 4.5:1. Score 7.0/10, high confidence.
Take-profit target: $42.07 (+49.5% upside). Target $42.07 (+49.4%), stop $26.18 (−7.5%), A.R:R 4.5:1. Stop-loss: $26.18.
Indivior Pharmaceuticals, Inc. trades at a P/E of 10.2 (forward 8.0). TrendMatrix value score: 9.0/10. Verdict: Strong Buy.
10 analysts rate INDV, with a consensus score of 4.2/5. 4 analysts publish price targets averaging $50.
What does Indivior Pharmaceuticals, Inc. do?Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine...
Indivior Pharmaceuticals markets two FDA-approved opioid use disorder treatments — SUBLOCADE (monthly buprenorphine injection, $856 million global net sales in 2025) and SUBOXONE Film ($346 million) — with 85% of net revenues generated in the U.S. SUBLOCADE accounted for 69% of total net revenues in 2025, distributed through a closed specialty pharmacy network.